醋酸阿比特龙治疗失败后低剂量恩杂鲁胺对一名转移性去势抵抗性前列腺癌患者产生显著疗效：一例报告
Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report.
作者信息
Rossi Luigi, Cimino Giuseppe, Gozzi Elisa, Sinjari Marsela, Brandi Martina, Ceddia Serena, Cosimati Antonella, Raimondi Lucrezia, Fontana Antonella, Filippi Luca, Bagni Oreste, Spinelli Gian Paolo
机构信息
UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
Department of Cellular Biotechnology and Hematology, University of Rome "Sapienza", Rome, Italy.
出版信息
Case Rep Oncol. 2021 Mar 31;14(1):634-640. doi: 10.1159/000514979. eCollection 2021 Jan-Apr.
We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide.
我们报告了一例老年转移性去势抵抗性前列腺癌患者，最初接受醋酸阿比特龙（1000毫克/天）联合促黄体生成素释放激素（LH-RH）拮抗剂、泼尼松（10毫克/天）和唑来膦酸治疗以控制骨转移。鉴于其较差的身体状况、疾病的影像学和生化进展，我们决定将阿比特龙换为恩杂鲁胺（160毫克/天）。由于不良事件，我们将恩杂鲁胺剂量减至80毫克/天。目前，尽管使用低剂量恩杂鲁胺，疾病仍得到控制。
Zotero 插件